CID16020046

GPR55 antagonist used in research, with no human data.

C₂₅H₁₉N₃O₄

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Data sheet

Names

IUPAC name: 4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid
Other names: CID 16020046 · MLS000675307 · SMR000314029 · GTPL6577

Identifiers

Formula: C₂₅H₁₉N₃O₄
Molar mass: 425.40 g/mol
CAS: 834903-43-4
PubChem CID: 16020046(new tab)
InChIKey: VGUQVYZXABOXCX-UHFFFAOYSA-N

Class

Family: ECS modulator (research)

Legal status

Status: Unscheduled

See the legal framework

Updated on 13 October 2026

Receptors and activity

GPR55Antagonist40 out of 100
CI50 de 1,18 µM (criblage PubChem AID 2013, antagonistes GPR55 par imagerie)
CB1Modulator3 out of 100
aucune constante d'affinité identifiée ; pas d'antagonisme dans des cellules HEK293 exprimant CB1 (Kargl et coll., 2013)
CB2Modulator3 out of 100
aucune constante d'affinité identifiée ; pas d'antagonisme dans des cellules HEK293 exprimant CB2 (Kargl et coll., 2013)

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 3 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 3 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 3 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 3 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 3 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

CID16020046 is a GPR55 antagonist, a receptor activated by lysophosphatidylinositol (LPI) and by certain cannabinoids, from the pyrazololactam chemical family. Its IC50 is 1.18 µM in the PubChem screen AID 2013. Published in 2013 as a selective antagonist of this receptor (Kargl et al., 2013), it was then used to study GPR55 in cells and in mice. It reduced inflammation in two colitis models (Stančić et al., 2015) and did not change atherosclerotic plaques in two atherosclerosis models (Montecucco et al., 2016). No human data or pharmacokinetic data have been identified in the sources consulted.

Key sources.

History

Source: Synthetic molecule: no natural source is reported in the sources consulted. The studies consulted are preclinical, in cells and in mice.

Origin (research tool)

No biosynthetic pathway: an organic synthetic molecule of the pyrazololactam family, built on a pyrazole ring fused to a five-membered lactam.

Legal framework

European Union: No harmonised control measure at European Union level has been identified in the sources consulted; any control falls under the national law of each member state.
France: Not classed as a narcotic in France. CID16020046 is not named in the ANSM consolidated list of narcotics (update of 16 February 2026). Its structure does not meet any generic family definition in that list: those definitions rest on indole, indazole, pyrrole bearing a naphthyl group, pyrrolo[3,2-c]pyridine, cyclohexylphenol or naphthylidene-indene cores, none of which is present here. It is not included in the INCB Green List 2026 either. No marketing authorisation has been identified in the sources consulted.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O
InChIKey: VGUQVYZXABOXCX-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.